Model Informed Drug Development Archives

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle Pillsbury2026年3月4日

Blog

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…

Certara2026年3月3日

Conference

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Danielle Pillsbury2026年3月2日

Blog

Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes

We cover the evidence of biosimulation improving clinical success rates, making the case for model-informed…

Certara2026年2月27日

ブログ

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

On Rare Disease Day 2026, Certara experts share how cross-functional innovation, regulatory strategies for rare…

Certara2026年2月26日

Live Events

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

– London, UK

Certara2026年2月24日

Webinar

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Danielle Pillsbury2026年2月23日

Blog

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Learn what the ICH M15 guideline means for Model-Informed Drug Development, regulatory credibility, harmonization, and…

Certara2026年2月18日

Guide

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Prepare for ICH M15 guideline: Learn how to assess model credibility, align terminology, and strengthen…

Certara2026年2月13日

Live Events

Certara IQ^™ Global Roadshow

Certara IQ™ is going on the road. From APAC to Europe to North America, our…

Certara2026年2月12日

Powered by Translations.com GlobalLink Web Software

モデルに基づく医薬品開発

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success

Apotekarsocieteten Clinical Pharmacology Strategies in Drug Development

Embracing Model-Informed Drug Discovery: The Path to Better Clinical Outcomes

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Biotech Forum: Workshop on Developing Investor-Ready Strategies

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

FAQs: The ICH M15 Guideline and What It Means for Model-Informed Drug Development

Guided by Evidence: Implementing the ICH M15 Guideline for Model-Informed Drug Development (MIDD)

Certara IQ^™ Global Roadshow

メルマガ登録

クイックアクセス

ソリューション

お問合せ